Cryoport posts 14% Q3 revenue growth, raises 2026 guidance again
Cryoport now supports a record 788 clinical trials and 23 commercial cell and gene therapies, and lifted its full-year revenue outlook to $197-199 million.
Cryoport reported third quarter 2026 revenue of $50.2 million, a 14% increase year-over-year, the company said in a November 5, 2026 release. During the quarter the company said it strengthened its position within the cell and gene therapy ecosystem, ending the period supporting 23 commercial therapies and a record 788 clinical trials worldwide.1 As of September 30, 2026, the number of commercial cell and gene therapies supported rose to 23 and total global clinical trial count climbed to 788, a net increase of 43 trials over September 30, 2025, with 99 of these trials in Phase 3.1
On the regulatory front, Cryoport customer Replimune received accelerated FDA approval in Q3 2026 for TUDRIQEV for treatment of adults with unresectable advanced cutaneous melanoma.1 Also during the quarter, Crispr Therapeutics and partner Vertex Pharmaceuticals received FDA supplemental approval expanding the label of CASGEVY to patients 2 years and older with Sickle Cell Disease or Transfusion-dependent Beta Thalassemia, making it the first approved genetic therapy for children as young as 2 for both conditions.1 The company said two customers filed Biologics License Applications with the FDA in the quarter, with another five possible BLA or Marketing Authorization Application filings anticipated in 2026, plus two additional possible therapy approvals tied to Q4 2026 PDUFA dates and one possible supplemental approval for geographic expansion.1
Operationally, Cryoport Systems initiated BioLogistics services at a new Global Supply Chain Center in Santa Ana, California,1 and its Paris, France center received ISO 9001 and ISO 21973 certifications, the latter being the first international standard developed specifically for transportation risks tied to human cells used therapeutically.1
Cryoport held $393.1 million in cash, cash equivalents, and short-term investments as of September 30, 2026.1 The company raised its full-year 2026 revenue guidance to a range of $197 million to $199 million.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.